Du är här

2015-10-01

Lumenis Ltd.: Lumenis Introduces the New Pulse(TM) 100H and Pulse(TM) 50H Holmium Laser Systems* Designed to Treat Any Size of Prostate and Any Size and Type o

Expanding Its Comprehensive Urology Portfolio, Lumenis Debuts Two Innovative Laser Systems for the Treatment of BPH and StonesLONDON, Oct. 1, 2015 (GLOBE NEWSWIRE) --Lumenis Ltd.(NASDAQ:LMNS), the world's
largest energy-based medical device company for surgical, aesthetic and
ophthalmic applications, announced the launch ofLumenis Pulse(TM)
100HandLumenis Pulse(TM) 50Hat the 33rdWorld Congress of Endourology (WCE),
taking place October 1 - 4, 2015 in London, UK.

Photos accompanying this release are available at

http://www.globenewswire.com/newsroom/prs/?pkgid=36578

http://www.globenewswire.com/newsroom/prs/?pkgid=36579

The Lumenis Pulse 100H, the next generation of the VersaPulse® PowerSuite(TM)
100 Watt system, is a versatile and enhanced laser solution for the treatment
of a wide array of clinical urologic indications including benign prostatic
hyperplasia (BPH), stones, tumors or strictures, along with a range of other
specialties such as general surgery, ENT, gynecology and pulmonary surgery.
As a greatly effective laser system for stones and BPH, the Pulse 100H
enables users to perform holmium laser enucleation of the prostate (HoLEP),
the gold standard treatment for BPH, and stone dusting(TM).

The new system features an improved design to enhance patient safety and
overall user experience. It offers a robust combination of laser parameters
addressing more than 70 types of procedures, an innovative pulse reshape
function for improved safety, dual pedals for improved ease of use, a
hands-free ready and standby mode for minimizing cost per procedure, and a
high energy per pulse of up to 3.5J with a high repetition rate of up to
50Hz.

In addition to the Pulse 100H, Lumenis will also be unveiling another key
addition to the Lumenis Pulse laser family, the Pulse 50H laser system.
Designed to efficiently address any type or size of stone in lithotripsy, the
Pulse 50H system is a superior comprehensive solution that provides 0.2J of
energy per pulse to minimize migration of even the smallest stone.
Furthermore, the Pulse 50H can be later upgraded to the new Pulse 100H,
allowing physicians to further leverage their investment as they grow their
practice.

"The new Pulse 50H system provides all features to perform modern intra
corporeal Holmium laser lithotripsy including a wide range of energy levels
and frequencies," said Professor Rassweiler, M.D., Ph.D., Klinikum SLK,
Heilbronn-Germany.

"With our commitment to the Endourological Society, we are proud to present
two new innovative systems, the Pulse 100H and 50H, to meet the developing,
dynamic market need in the field of minimally invasive urological surgery,"
said Tzipi Ozer-Armon, CEO of Lumenis. "The additions to the Pulse platform
series signify a key improvement to our current urological solutions for
HoLEP and stone dusting and empower users to achieve more than 70 types of
procedures in a range of clinical specialties."

To learn more about the Lumenis Pulse 100H and 50H from leading clinical
experts, please visit the company's booth # 411 during the following times:

Friday, October 2

--------------------------------------------------------------------------------------
| 14:00 Lumenis' New Solution for Vaporization/Pulse 120H + Xpeeda Fiber |
| Speaker: Dr. Mark E. Leo, US |
| |
| 15:00 HoLEP vs. TURP: A Cost Analysis |
| Speaker: Mr. Mark Cynk, UK |
| |
| 15:45 Lumenis Pulse 120H and the New SlimLine 200 D/F/L for Flexible Ureteroscopy |
| Speaker: Dr. Marc Beaghler, US |
| |
| 16:30 HoLEP Technique Improvements with the New Lumenis Pulse 100H |
| Speaker: Mr. Gerald Rix, UK |
| |
| 17:15 HoLEP Technique Improvements with the New Lumenis Pulse 100H |
| Speaker: Mr. Gerald Rix, UK |
--------------------------------------------------------------------------------------
Saturday, October 3

---------------------------------------------------------------------------------------
| 13:00 Lumenis' Pulse 120H and the New SlimLine 200 D/F/L for Flexible Ureteroscopy |
| Speaker: Dr. Marc Beaghler, US |
| |
| 13:45 Lumenis' New Solution for Vaporization/Pulse 120H + Xpeeda Fiber |
| Speaker: Dr. Mark E. Leo, US |
| |
| 14:15 HoLEP vs. TURP: A cost analysis |
| Speaker: Mr. Mark Cynk, UK |
| |
| 15:00 Personal Experience of the New Lumenis Pulse 50H Used in Stone Cases |
| Speaker: Prof. Jens Rassweiler, Germany |
| |
| 15:45 Lumenis Pulse 120H and the New SlimLine 200 D/F/L for Flexible Ureteroscopy |
| Speaker: Dr. Marc Beaghler, US |
| |
| 16:30 Lumenis' New Solution for Vaporization/Pulse 120H + Xpeeda Fiber |
| Speaker: Dr. Mark E. Leo, US |
---------------------------------------------------------------------------------------
Sunday, October 4

--------------------------------------------------------------------------------------
| 09:00 Lumenis Pulse 120H and the New SlimLine 200 D/F/L for Flexible Ureteroscopy |
| Speaker: Dr. Marc Beaghler, US |
| |
| 10:00 Lumenis' New Solution for Vaporization/Pulse 120H + Xpeeda Fiber |
| Speaker: Dr. Mark E. Leo, US |
| |
| 10:45 Personal Experience of the New Lumenis Pulse 50H Used in Stone Cases |
| Speaker: Prof. Jens Rassweiler, Germany |
| |
| 11:30 Personal Experience of the New Lumenis Pulse 50H Used in Stone Cases |
| Speaker: Prof. Jens Rassweiler, Germany |
| |
| 13:00 Lumenis' New Solution for Vaporization/Pulse 120H + Xpeeda Fiber |
| Speaker: Dr. Mark E. Leo, US |
--------------------------------------------------------------------------------------
* The Lumenis Pulse 100H and Lumenis Pulse 50H are not yet available in the
United States.

About Lumenis
Lumenis (NASDAQ:LMNS) is a global leader in the field of minimally-invasive
clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and
is a world-renowned expert in developing and commercializing innovative
energy-based technologies, including Laser, Intense Pulsed Light (IPL) and
Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products
have redefined medical treatments and have set numerous technological and
clinical gold-standards. Lumenis has successfully created solutions for
previously untreatable conditions, as well as designed advanced technologies
that have revolutionized existing treatment methods. For more information
visit: www.lumenis.com

Forward-Looking Statements

Information provided in this press release may contain statements relating to
current expectations, estimates, forecasts and projections about future
events that are "forward-looking statements" as defined in the Private
Securities Litigation Reform Act of 1995. These forward-looking statements
may include but are not limited to the Company's plans, objectives and
expectations for future operations, including its projected results of
operations. Forward-looking statements are often characterized by the use of
forward-looking terminology such as "may," "will," "expect," "anticipate,"
"estimate," "continue," "believe," "should," "intend," "plan," "project" or
other similar words, but are not the only way these statements are
identified. These forward-looking statements are based upon our management's
current estimates and projections of future results or trends. Actual results
may differ materially from those projected as a result of certain risks and
uncertainties, including those risks discussed under the heading "Risk
Factors" in our most recent Annual Report on Form 20-F filed with the U.S.
Securities and Exchange Commission. These forward-looking statements are made
only as of the date hereof, and the Company undertakes no obligation to
update or revise the forward-looking statements, whether as a result of new
information, future events or otherwise.

CONTACT: For further information:

Glenn Silver
Lazar Partners Ltd.
(646) 871-8495

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lumenis Ltd. via Globenewswire

HUG#1955895

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.